CD274 and cancer: While existing biomarkers such as PD‐L1 expression and tumor mutational burden (TMB) offer limited predictive value and often lack consistency across cancer types, the VGS‐based approach captures key features of effective anti‐tumor immunity derived from naturally occurring immune activation, providing a biologically grounded and broadly applicable alternative.